Cell And Gene Therapies Will Unlock Biopreservation Potential
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
28 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$31.30
18.1% undervalued intrinsic discount15 Aug
US$25.65
1Y
-1.3%7D
4.7%